Literature DB >> 1450287

Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics.

L E Adler1, L J Hoffer, J Griffith, M C Waldo, R Freedman.   

Abstract

Diminished gating of the P50 auditory evoked response to repeated stimuli is a psychophysiological feature of schizophrenia, that is also present in many relatives of patients. Animal models of auditory sensory gating indicate that nicotinic cholinergic neurotransmission is a critical neuronal substrate. The aim of this experiment was to determine if the deficit in sensory gating could be reversed by nicotine administration. Nonsmoking relatives of schizophrenics with abnormal sensory gating were selected as subjects for this initial double-blind trial, to avoid effects of psychotropic medications that might complicate trials in schizophrenic patients themselves. Nicotine-containing gum increased P50 sensory gating to near normal levels within 30 min of administration. The effect was transient; the gating of P50 returned to baseline levels within 1 hr. There was no change observed after placebo administration. In one of the subjects, the anticholinesterase inhibitor physostigmine similarly normalized P50 gating. The results are consistent with the hypothesis that nicotinic cholinergic neurotransmission may mediate a familial psychophysiological deficit in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1450287     DOI: 10.1016/0006-3223(92)90073-9

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  98 in total

Review 1.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Nicotine suppresses the P13 auditory evoked potential by acting on the pedunculopontine nucleus in the rat.

Authors:  N Mamiya; R Buchanan; T Wallace; R D Skinner; E Garcia-Rill
Journal:  Exp Brain Res       Date:  2005-03-08       Impact factor: 1.972

4.  Gamma and beta neural activity evoked during a sensory gating paradigm: effects of auditory, somatosensory and cross-modal stimulation.

Authors:  Michael A Kisley; Zoe M Cornwell
Journal:  Clin Neurophysiol       Date:  2006-09-27       Impact factor: 3.708

Review 5.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

6.  Neuronal effects of nicotine during auditory selective attention.

Authors:  Jason Smucny; Ann Olincy; Lindsay S Eichman; Jason R Tregellas
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

7.  Role of nicotinic receptors in the lateral habenula in the attenuation of amphetamine-induced prepulse inhibition deficits of the acoustic startle response in rats.

Authors:  José A Larrauri; Dennis A Burke; Brandon J Hall; Edward D Levin
Journal:  Psychopharmacology (Berl)       Date:  2015-04-28       Impact factor: 4.530

Review 8.  Sensory gating: a translational effort from basic to clinical science.

Authors:  Howard C Cromwell; Ryan P Mears; Li Wan; Nash N Boutros
Journal:  Clin EEG Neurosci       Date:  2008-04       Impact factor: 1.843

9.  Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.

Authors:  Merilyne C Waldo; Laurie Woodward; Lawrence E Adler
Journal:  Psychiatry Res       Date:  2009-12-02       Impact factor: 3.222

10.  Effects of COMT genotype on sensory gating and its modulation by nicotine: Differences in low and high P50 suppressors.

Authors:  S de la Salle; D Smith; J Choueiry; D Impey; T Philippe; H Dort; A Millar; P Albert; V Knott
Journal:  Neuroscience       Date:  2013-03-25       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.